Terns Pharmaceuticals Inc., trading on NASDAQ under the symbol TERN, has released a corporate presentation highlighting its progress as of June 2025. The company is advancing two differentiated clinical assets, TERN-701 and TERN-601, with significant milestones anticipated in the fourth quarter of 2025. TERN-701, an allosteric BCR-ABL inhibitor, aims to address chronic myeloid leukemia $(CML.UK)$ in a market exceeding $5 billion. Meanwhile, TERN-601, an oral GLP-1 receptor agonist, targets obesity with potential competitive weight loss and superior tolerability. Both programs are progressing through clinical trials, with TERN-701 in Phase 1 and TERN-601 in Phase 2. Terns Pharmaceuticals has secured a cash runway of $334 million to support its development pipeline into 2028. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。